Argenx (NASDAQ:ARGX) is set to implement a leadership change in May, a development that UBS Global Research believes should ...

Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO ...

After shepherding the company through its first approval and the successful launch of blockbuster autoimmune drug Vyvgart, ...

Argenx CEO Tim Van Hauwermeiren is stepping down in May and will be succeeded by Karen Massey, the Belgian drugmaker's COO.

An update from Argenx Se ( ($ARGX) ) is now available. On January 5, 2026, Argenx SE announced a planned leadership transition designed to support ...

A Gilead Sciences executive who left the San Fransisco pharmaceutical giant last month after nearly four years, has been ...

Novo Nordisk officially began marketing the pill version of its popular weight loss drug. Elsewhere, Sanofi bought a vaccine ...

Chief executive Tim Van Hauwermeiren will transition to chairman of the board, while Chief Operating Officer Karen Massey is set to become CEO effective May 6, subject to shareholder approval. UBS ...

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro Stoxx 50 Index and smaller names including Valneva SE and Inventiva also ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional ...

Across the recent three months, 11 analysts have shared their insights on argenx (NASDAQ:ARGX), expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Buying $100 In ARGX: If an investor had bought $100 of ARGX stock 5 years ago, it would be worth $284.76 today based on a price of $837.45 for ARGX at the time of writing.